Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults
Clinical trial NCT04645147 · COMPLETED
Trial details
- NCT number
- NCT04645147
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-29
- Primary completion
- 2025-07-01
- Enrollment
- 83
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.